Magnetic Bead Screening Kit for Primary Aldosteronism

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for diagnosing primary aldosteronism face challenges due to cross-reactivity in aldosterone/renin activity tests, interference from therapeutic drugs, and differential diagnosis complexities, leading to inconsistent results and potential misdiagnosis.

Innovation Solution

A screening kit and diagnosis system using magnetic beads with balanced hydrophilic-lipophilic polymers for simultaneous detection of aldosterone, angiotensin I, angiotensin II, cortisol, 18-hydrocorticosterone, and 18-Hydroxy Cortisol via liquid chromatography-tandem mass spectrometry, with a cut-off ARR value of 20.4 for accurate PA screening and typing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If radioimmunoassay or chemiluminescent immunoassay is used to measure aldosterone, then the test is rapid and easy to implement, but cross-reactivity occurs between antibodies and non-eliminated aldosterone metabolites causing significantly overestimated test results

Engineering Contradiction:

Improvetest implementation easeVSAvoidaldosterone test result accuracy

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent extracts and removes aldosterone metabolites from the sample before performing the immunoassay. By eliminating the interfering metabolites that cause cross-reactivity, the test achieves both ease of implementation and accurate results without the overestimation problem

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces an intermediary step (metabolite removal process) between sample collection and immunoassay. This intermediary action eliminates the harmful cross-reactivity while preserving the simplicity of the subsequent immunoassay procedure

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If patients withdraw conventional hypotensive drugs for 4-6 weeks during screening, then drug interference is eliminated, but false-positive or false-negative screening results occur and clinical implementation becomes difficult

Engineering Contradiction:

Improvescreening result accuracyVSAvoidclinical implementation ease

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent converts the harmful effect of drug interference into a beneficial diagnostic tool by detecting and identifying the interfering drugs. Instead of requiring drug withdrawal, the system uses the presence of these drugs as information to adjust or interpret screening results, eliminating the need for difficult clinical protocols

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If aldosterone/renin activity test is used as the preferred screening indicator, then screening can be performed, but inconsistent results occur due to cross-reactivity and matrix effects

Engineering Contradiction:

Improvescreening efficiencyVSAvoidARR test result consistency

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent performs preliminary removal of aldosterone metabolites and interference substances before conducting the aldosterone/renin activity test. This preliminary action prevents cross-reactivity and matrix effects from affecting the subsequent screening, ensuring both efficiency and consistent results

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a reliable and accurate method for early detection and typing of primary aldosteronism, improving sensitivity and specificity, and reducing the impact of drug interference and matrix effects, enabling effective therapeutic interventions.

Implementation Method 1

a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof is used to adsorb 6 markers in the blood sample

Methodology Applied

Scientific EffectAdsorption: Adsorption

Implementation Method 2

detected by liquid chromatography-tandem mass spectrometry

Methodology Applied

Scientific EffectChromatography: Chromatography

Implementation Method 3

liquid chromatography-tandem mass spectrometry to test the content of the 6 markers in the blood sample

Methodology Applied

Scientific EffectMass spectrometry:

Data Source

PatentUS20240110929A1Screening kit and diagnosis system for primary aldosteronism

Publication Date: 2024.04.04 CALIBRA SCIENTIFIC INC

AI summary

The present invention provides a screening kit and a confirmed and typing diagnosis system for primary aldosteronism. A sample is pretreated by a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof, and process conditions are optimized and the content of each the six markers such as, aldosterone in the sample is accurately detected by liquid chromatography-tandem mass spectrometry for one time, thus finding the optimal screening cut-off value of 20.4; when a positive result is judged, PA is confirmed and subjected to typing diagnosis according to the test values of the markers, thereby achieving the simultaneous detection of the content of each the six markers such as, aldosterone on the same platform. Therefore, the present invention is integrated with screening, confirmed and typing diagnosis functions, thus providing a reliable laboratory examination basis for clinicians to formulate an effective therapeutic regimen.